| 21.01 0.3 (1.45%) | 12-05 10:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.84 | 1-year : | 30.18 |
| Resists | First : | 22.12 | Second : | 25.84 |
| Pivot price | 20.11  |
|||
| Supports | First : | 16.63 | Second : | 13.23 |
| MAs | MA(5) : | 20.29  |
MA(20) : | 19.37 |
| MA(100) : | 14.69 |
MA(250) : | 0 | |
| MACD | MACD : | 1.3 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 67.7 |
D(3) : | 64.3 |
| RSI | RSI(14): 63.7 |
|||
| 52-week | High : | 38.27 | Low : | 9.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TNDM ] has closed below upper band by 36.1%. Bollinger Bands are 9.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.79 - 20.87 | 20.87 - 20.96 |
| Low: | 19.48 - 19.57 | 19.57 - 19.66 |
| Close: | 20.55 - 20.69 | 20.69 - 20.85 |
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Thu, 04 Dec 2025
Taking Stock of Tandem Diabetes Care (TNDM) Valuation After Fresh Analyst Upgrades and Reaffirmed Optimism - simplywall.st
Wed, 03 Dec 2025
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM - PR Newswire
Wed, 03 Dec 2025
Tandem Diabetes (TNDM) Stock Is Up, What You Need To Know - Markets Financial Content
Tue, 02 Dec 2025
Assessing Tandem Diabetes Care’s (TNDM) Valuation After Legal Probe and t:slim X2 Pump Correction Announcement - Yahoo Finance
Tue, 02 Dec 2025
TNDM: Morgan Stanley Raises Price Target Amidst Maintained Ratin - GuruFocus
Sat, 22 Nov 2025
Why Tandem Diabetes Care (TNDM) Is Up 14.3% After FDA Clears Android App for Mobi System and What’s Next - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 68 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 115.1 (%) |
| Shares Short | 8,790 (K) |
| Shares Short P.Month | 9,240 (K) |
| EPS | -3.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.96 |
| Profit Margin | -20.2 % |
| Operating Margin | -9.2 % |
| Return on Assets (ttm) | -6 % |
| Return on Equity (ttm) | -109.8 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | 7.9 |
| Sales Per Share | 14.89 |
| EBITDA (p.s.) | -1.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 13 (M) |
| PE Ratio | -6.84 |
| PEG Ratio | 0 |
| Price to Book value | 10.57 |
| Price to Sales | 1.39 |
| Price to Cash Flow | -159.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|